An editorial notes that in US, implementation of expanded quality metrics, incentives, and systems that facilitate safer prescribing practice around drug combinations will take time. It suggests a multi-pronged effort from both regulators and experts writing clinical guidelines, along with extensive expansion in warnings about the hazards of drug-drug interactions, are essential to reduce low value, potentially dangerous care.